DRI Capital Inc. Updates Executive Changes

TORONTO, September 27, 2024  – DRI Healthcare Trust recently announced that its investigation into consulting and other expenses submitted had substantially concluded. DRI did not find Chris Anastasopoulos to have submitted any inappropriate consulting or other expenses. Mr. Anastasopoulos has since advised DRI Capital that he has decided to resign to pursue other opportunities. He will remain with DRI Capital to assist with a transition period to October 31, 2024.

DRI Capital wishes Mr. Anastasopoulos well in his future endeavours and thanks him for his contributions.

Recent Posts

DRI Healthcare to Host Second Quarter 2025 Earnings Call and Webcast on August 14, 2025

DRI Healthcare Comments on FDA Approval and our Increased Investment in KalVista Pharmaceuticals' Ekterly® (sebetrals...

DRI Healthcare Announces Closing of Internalization Transaction